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Objectives: Urothelial carcinoma (UC) aggressiveness is determined by tumor inherent molecular characteristics, such as molecular
subtypes, as well as by host reactions directed toward the tumor. Cell types responsible for the host's response include tumor-inﬁltrating
lymphocytes (TILs) and tumor-associated macrophages (TAMs). The aim of the present investigation was to explore the immunological
response in relation to UC molecular subtypes and to evaluate the prognostic effect of TIL and TAM counts in tissue sections from muscle-
invasive (MI) tumors.
Methods and materials: Tissue microarrays with 296 tumors spanning all pathological stages and grades were analyzed with antibodies
for CD3, CD8, FOXP3, CD68, and CD163. Cases were classiﬁed into the following molecular subtypes: urobasal, genomically unstable,
and squamous cell carcinoma–like using a combination of immunohistochemistry and histology. The Cox regression and Kaplan-Meier
analyses were performed with progression-free survival and disease-speciﬁc survival as end points.
Results: UC molecular subtypes demonstrate different degrees of immunological responses; the urobasal subtype induces a weak
response, the genomically unstable subtype induces an intermediate response, and the squamous cell carcinoma–like subtype induces a
strong response. These subtype speciﬁc responses are independent of tumor stage and include both TILs and TAMs. The presence of
inﬁltrating CD3þ TILs was signiﬁcantly associated with good prognosis in the MI cases (Po 0.01). This positive association was
modulated by the presence of CD68þ TAMs. The strongest association with poor survival was observed for a high ratio between CD68 and
CD3 (P ¼ 7  105).
Conclusion: UC molecular subtypes induce immunological responses at different levels. A high CD68/CD3 ratio identiﬁes a bad
prognosis group among MI UC cases. r 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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The inherent molecular characteristics of urothelial
carcinomas (UCs) determine their aggressiveness. For
instance, low-stage low-grade UCs with a small propensity
to progress show very different molecular proﬁles compared
to muscle-invasive (MI) cases [1]. However, molecular
proﬁles also differ among pathologically similar tumors.
We recently showed that UCs may be classiﬁed intoess article under the CC BY-NC-SA license
Table 1
Distribution of molecular subtype and patient/tumor data across
pathological stages
Ta, n ¼ 112 T1, n ¼ 89 MI, n ¼ 93 Tx, n ¼ 2
Molecular subtype, no. of cases
Urobasal 98 34 11 2
GU 9 43 46 0
SCC-like 0 4 34 0
Not classiﬁed 5 8 2 0
Patient/tumor data
Age, mean years 69.1 70.8 71.7 75.0
Gender, no. of cases
Male 77 72 69 2
Female 35 17 24 0
Tumor grade, no. of cases
G1 42 0 0 0
G2 62 31 10 1
G3 8 58 83 1
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unstable (GU), and squamous cell carcinoma–like (SCCL)
tumors using immunohistochemistry (IHC) [2] and that
Ta tumors are dominated by the Uro cases, T1 tumors by
Uro and GU cases, and MI tumors by GU and SCCL cases.
The tumor subtypes show distinct molecular proﬁles at both
RNA [3] and protein [2] levels, as well as distinct survival
characteristics. However, the outcome of a given tumor is
also affected by host reactions toward the tumor cells.
Tumor-inﬁltrating lymphocytes (TILs) are a heterogeneous
group of immune cells that are abundant in tumors of
different origin. Cytotoxic T cells (CTLs) are the main
effector cells in antitumor T-cell immunity, and their
activity is modulated by other T-cell subtypes, such as
T-helper cells and regulatory T cells (Tregs). The effect
of a particular immune response is determined by the
balance between the various T-cell subtypes involved.
It has previously been shown that tumor inﬁltration by
both CTLs (CD8þ) and T cells in general (CD3þ)
promotes survival in patients with UC [4,5]. Another
important immune cell population present in tumors is
tumor-associated macrophages (TAMs). As for T cells,
macrophages may have activating (M1), or suppressive
(M2) immune functions. TAMs have previously been sug-
gested to be M2-like [6]. They secrete a wide range of
cytokines and have an important role in immune suppres-
sion, angiogenesis, and tumor progression. Consequently,
TAMs may have an overall tumor growth–promoting
effect, counteracting the action of the T-cell response
[7,8]. Thus, in the present investigation, we have evaluated
the level of both TILs and TAMs in 296 cases of UC and
related the immune response to UC molecular subtypes
and clinical outcome.2. Materials and methods
2.1. Patient and sample selection
Tumor biopsies from transurethral resection of 296
patients diagnosed with UC in the Southern Sweden
Healthcare Region between 2001 and 2009 were included.
Patient and tumor data are summarized in Table 1. Of the
patients with non-MI (NMI) tumors, 56 received bacillus
Calmette-Guérin (BCG) treatment (6 instillations), of the
patients with MI tumors 52 were treated with radical
cystectomy, and of these 4 with additional neoadjuvant
chemotherapy. The majority of the cases included were
primary tumors; approximately 1 in 5 tumors (54 cases) had
a history of bladder cancer. Median follow-up time was 51
months for patients with NMI disease and 70 months for
patients with MI disease. The investigation was approved
by the regional ethics committee (no. 2010/5). The tissue
sections were reevaluated by a uropathologist (G.C.) using
TNM 2009 [9], as staging and grading was performed
according to the World Health Organization 1999 system.2.2. Tissue microarrays and IHC
Tissue microarray blocks were constructed from 1.0-mm
punches of formalin-ﬁxed parafﬁn-embedded specimens of
transurethral resection of the bladder using a manual array
(TMA arrayer, Pathology Devices, Inc, Westminster, MD).
Tissue punches were collected from areas with the highest
grade on the corresponding sections and from areas without
necrosis. Tissue microarray (TMA) sections were stained
with antibodies against CD3, CD8, FOXP3, CD68, and
CD163. As negative controls, the primary antibodies were
omitted for each staining. Antibodies for CD3 (clone,
F7.2.38; mouse; dilution, 1:200; product M7254; Dako),
CD8 (clone, C8/144B; mouse; dilution, 1:50; product
M7103; Dako), FOXP3 (clone, 236A/E7; mouse; dilution,
1:1,000; product ab20034; Abcam), CD163 (clone, 10D6;
mouse; dilution, 1:250; product NCL-CD163; Novocastra),
and CD68 (clone, EBM11; mouse; dilution, 1:1,500;
product M0718; Dako) were used. All markers showed
discrete cellular-staining patterns. Each TMA core was
given a score of 0 to 5 based on the average count of
positive cells per tissue area. The scores 0 to 5 corresponded
approximately to the bins 0 to 20, 20 to 50, 50 to 100, 100
to 300, 300 to 500, and4500 positive cells per TMA core.
The range of scoring intervals was deﬁned to capture the
observed variation for each individual marker. For each
marker, 1 case per bin was manually counted, and these
cases were used as a reference in the evaluation process.
The evaluations were done manually by 2 observers. When
the opinions differed, both the observers discussed the case
and reached an agreement. For most cases (n ¼ 287),
2 cores were available, and the mean of the 2 cores was
used. Marker scores were recorded for the entire core and
separately for the intratumoral and stromal compartments
when the distinction between both the compartments was
clear. The evaluations were performed on digitalized
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at 40 magniﬁcation.
2.3. Tumor classiﬁcation and statistical analysis
Tumor cases were classiﬁed into the molecular subtypes
Uro, GU, and SCCL as described in Sjödahl et al. [2] using
the variables urothelial-like growth pattern, World Health
Organization 1999 grade 3, and CCNB1, CCND1, and KRT5
IHC data. Anti–α-smooth muscle actin antibody was used to
facilitate the identiﬁcation of tumor stroma as described
previously [2]. Mann-Whitney U test or Kruskal-Wallis rank
sum test was used to test marker score differences between
the sample groups. The Cox regression model was used to
investigate association with outcome. All markers were
analyzed for univariate association to progression-free sur-
vival for NMI cases and disease-speciﬁc survival (DSS) for
MI cases. Progression of NMI included progression to MI or
to cystectomy. Only patients with MI tumors who received
curative treatment, i.e., cystectomy, were included in the
analysis of DSS (n ¼ 52). Pathological data from cystectomy
specimens were not used as such information is not available
at the time of treatment decision. Instead, clinical stage was
used in the multivariate analysis of MI tumors. As all but 2 of
the 52 cystectomized cases were G3, grade was not consid-
ered informative in the Cox regression analyses. CD68 and
CD3 were tested also in a bivariate model of DSS to dissect
the independence of associations. P-values for Kaplan-Meier
analyses were estimated by log-rank tests. All statistical tests
were performed using R.3. Results
We produced a TMA consisting of 296 cases (Table 1)
and applied antibodies for CD3 (T cells in general), CD8
(CTLs), FOXP3 (Tregs), CD68 (TAMs in general), and
CD163 (M2-like TAMs). As expected from the subcellular
localization of the target proteins, antibodies against CD3,
CD8, and CD163 showed membranous staining; FOXP3
nuclear staining; and CD68 showed cytoplasmic staining.
The size and morphology of labeled cells were consistent
with T cells and macrophages, respectively. Tumor cell
positivity was only observed for CD68 and CD163 and only
in a small subset of UCs (14 cases, 5%, for CD68, and 18
cases, 6%, for CD163) in which staining was generally
weak and cytoplasmic. Overall, the markers CD3, CD8,Table 2
Pearson correlation coefﬁcients between T-cell and macrophage markers
CD3 CD8 FOXP3 CD68 CD163
CD3 1.00 – – – –
CD8 0.79 1.00 – – –
FOXP3 0.70 0.62 1.00 – –
CD68 0.72 0.74 0.60 1.00 –
CD163 0.75 0.78 0.60 0.88 1.00CD68, and CD163 showed pair-wise strong correlations
R4 0.7 (Table 2), i.e., T-cell marker scores were corre-
lated with macrophage marker scores. This suggests that the
immunological response in most cases involves both T cells
and macrophages. The coordinated response among T cells
and macrophages was also evident in cases where a clear
separation between tumor parenchyma and stromal com-
partments was visible; either all labeled cells, irrespectively
of marker, were localized to the stroma, or to both stroma
and tumor parenchyma (Fig. 1). We observed cases with
both moderate and strong positivity (inﬁltration) in stroma
only and cases with strong positivity in both compartments
(Fig. 1). However, no cases with strong positivity in tumor
parenchyma only were observed.
We next applied the previously described IHC/histopa-
thology classiﬁer [2] to group cases into the 3 major
molecular subtypes of UC, Uro, GU, and SCCL (Fig. 2).
The subtypes represent major clinicopathological entities of
UC with characteristic molecular and prognostic features [3]
and only show moderate overlap with pathological tumor
stage (Table 1). In Fig. 2, we have plotted the immune-
marker scores for each tumor subtype when present in Ta,
T1, and MI cases. Ta cases show low counts for all markers
and no differences were observed between Ta Uro and Ta
GU cases, except for a modest difference in CD68 counts.
However, signiﬁcant differences were seen between Uro,
GU, and SCCL cases within stage T1, particularly with
respect to macrophage counts. T-cell markers showed a
similar but less pronounced pattern. The same pattern of
differential labeling was also observed among MI cases. To
further substantiate the relationship between molecular
subtype and inﬁltration, we created linear models where
the inﬂuence of tumor stage and molecular subtype on
marker scores was evaluated. When correcting for stage,
molecular subtype has a signiﬁcant inﬂuence on scores for
all the markers (CD3, P ¼ 0.014; CD8, Po 2  106;
FOXP3, Po 2  104; CD68, Po 4  105; CD163,
Po 3  106). Conversely, when correcting for molecular
subtype, pathological stage had a signiﬁcant inﬂuence on 3
of the markers (CD3, P ¼ 0.0021; CD68, Po 2  105;
CD163, Po 6  105).
Hence, both molecular subtypes and pathological stage
are associated with different levels of immunological
responses. Notably, Uro cases show the weakest, GU the
intermediate, and SCCL the strongest response, irrespective
of tumor stage, suggesting that the relative strength of the
induced response is intrinsic to the molecular subtype.
Next, we wanted to investigate the prognostic signiﬁ-
cance of tumor-inﬁltrating immunological cells. Scores for
stromal, intratumoral, and total biopsy were analyzed
separately when the distinction could be made. In no
instance did the stromal or intratumoral score show stronger
association with any outcome than the total score, irrespec-
tive of marker. We analyzed immune cell marker associa-
tion to progression-free survival in NMI tumors. Although
the low number of progression events (n ¼ 24) in this
Fig. 1. Representative images of immune cell marker staining in UC. (A) Anti-α-SMA staining was used to facilitate the distinction between stromal (positive)
and intratumoral (negative) compartments when present. (B) Representative staining is shown for 5 cases. The areas shown are indicated by the dashed lines in
(A). From top down, urobasal tumor without inﬁltration, urobasal tumor with dense inﬁltration of the tumor adjacent stroma, genomically unstable tumor with
moderate inﬁltration of both stromal and intratumoral compartments, genomically unstable tumor with dense inﬁltration and no distinct intratumoral and
stromal compartments, and a SCC-like tumor with dense inﬁltration and no distinct intratumoral and stromal compartments. SMA ¼ smooth muscle actin
antibody. (Color version of ﬁgure is available online.)
G. Sjödahl et al. / Urologic Oncology: Seminars and Original Investigations 32 (2014) 791–797794patient cohort reduced the statistical power of Cox regres-
sion analyses, the macrophage marker CD68 showed
borderline signiﬁcance (hazard ratio [HR] ¼ 1.523;
CI (95%): 1.082–2.144; P ¼ 0.016). However, owing to
the few progression events in this cohort, no further
subdivision of BCG-treated and non–BCG-treated patients
could be done. Next, we divided the MI cases by inﬁltration
into “high” and “low” scoring cases by applying a threshold
at the midpoint score 3 or greater. In the MI cases treated
with radical cystectomy, univariate Cox regression with
DSS as end point revealed that CD3 scores above this
threshold were associated with a better patient survival
(P ¼ 0.009) (Table 3). The result was not improved by
using the full range of scores, suggesting a threshold effect.
The subsequent Kaplan-Meier analysis clearly identiﬁed a
good prognosis group composed of CD3 high cases
(Fig. 3A). Pair-wise bivariate tests, again with DSS as the
end point, revealed both CD3 and CD68 as signiﬁcant
variables; CD3þ counts associated with good (HR ¼ 0.5;95% CI: 0.29–0.69; P ¼ 3  104) and CD68 counts with
a bad prognosis (HR ¼ 1.7; 95% CI: 1.14–2.51; P ¼
0.0096). To investigate the opposite actions of CD3þ and
CD68þ counts further, we divided the cases into CD68
high/low in analogy with CD3 using a threshold of 3,
resulting in 4 groups; CD3 high/CD68 low; CD3 high/
CD68 high; CD3 low/CD68 low; and CD3 low/CD68 high,
and we performed a 4-group Kaplan-Meier analysis
(Fig. 3B). This analysis revealed a best prognosis group
of patients with CD3 high and CD68 low and a worst
prognosis group with CD3 low and CD68 high. In fact, all
patients in the CD3 low/CD68 high group succumbed to
their disease within 20 months. This result suggests that
CD68 adds information on outcome to both the CD3 high
and the CD3 low group but does not necessarily have
prognostic value on its own. We, therefore, calculated a
CD68/CD3 ratio based on the marker scores for each tumor
and used these ratios in subsequent Cox regression
(Table 3) and Kaplan-Meier analyses (Fig. 3C). This greatly
Fig. 2. Box plots of immune cell marker scores in molecular subtypes of
UC, stratiﬁed by tumor stage. P-values shown when signiﬁcant, Po 0.05.
Mann-Whitney U test for pair-wise comparison, Kruskal-Wallis rank sum
test for comparisons across the 3 groups.
Table 3
Univariate and multivariate Cox regression analyses: Disease-speciﬁc
survival of muscle-invasive cases where the patient underwent cystectomy
(n ¼ 52)
HR CI (95%) P-value
Univariate
CD3 total 0.60 0.41–0.89 0.009
CD8 total 0.82 0.57–1.16 0.26
FOXP3 total 0.83 0.56–1.22 0.34
CD68 total 1.16 0.82–1.62 0.40
CD163 total 0.99 0.69–1.41 0.95
Ratio (univariate)
CD68/CD341 1.67 1.26–2.21 6.9  105
Multivariate
Clinical stage4T2 5.37 2.09–13.81 4.9  104
CD68/CD341 7.73 3.13–19.10 9.5  106
P-values o 0.05 are indicated in bold.
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cases with CD68/CD3 ratios above 1, 14 patients (82%) had
succumbed to their disease within 3 years. In multivariate
analysis, we included clinical stage (T2 vs.4T2) and the
CD68/CD3 ratio. Only the CD68/CD3 ratio was used in this
analysis, as the CD3 total had a smaller prognostic effect in
univariate analysis and because the ratio and CD3 total are
not independent variables. Too few patients had a positive
clinical node status (n ¼ 5) or received neoadjuvant
chemotherapy (n ¼ 4) to be included in multivariate
analyses. Both clinical stage and CD68/CD3 ratio wereindependently associated to DSS (Table 3). No signiﬁcant
associations with outcome were observed for CD163, CD8,
or FOXP3 in any analysis.
4. Discussion
We performed IHC using 3 T-cell markers, CD3 for
T cells in general, CD8 for CTLs, and FOXP3 for Tregs
[10], and 2 macrophage-speciﬁc markers, CD68 for macro-
phages in general [11], and CD163 for M2-like macro-
phages [12] to evaluate inﬁltrating immunological cells in
UC. In general, T-cell and macrophage inﬁltration was
highly correlated, albeit with the possible exception for
Tregs (FOXP3). This indicates that in most cases inﬁltration
by immunological cells encompass a complex set of cells,
including both T cells and macrophages. The level of
inﬁltration varied considerably from a few isolated immu-
nological cells to massive inﬁltration. In fact, in a previous
whole-genome gene expression analysis of UC, we identi-
ﬁed cases that showed a gene expression signature domi-
nated by an immunological proﬁle to such an extent that
they formed a separate group of “inﬁltrated” tumors [3]. As
expected, the level of inﬁltration varied across the tumor
stages. This is most likely due to differences in invasion
depth and level of damage to the surrounding tissue. It has
also been shown that the cytokine proﬁles of MI tumors
differ radically from that of NMI tumors [13]. Furthermore,
it has been shown that bladder TILs are in an activated state
[14]. Even though the level of immune inﬁltration was
highly stage dependent, we observed signiﬁcant differences
between the molecular subtypes Uro, GU, and SCCL within
the same stage group. Among T1 cases, Uro showed the
lowest, GU showed intermediate, and SCCL showed the
highest TIL and TAM counts. This was particularly evident
with respect to inﬁltrating macrophages. It could be argued
that the differential response seen among molecular sub-
types for T1 cases is associated with the pathological grade,
and not with molecular subtype, as GU tumors are of grade
Fig. 3. Kaplan-Meier estimates of disease-speciﬁc survival in cystectomized muscle-invasive cases. (A) CD3þ high vs. CD3þ low cases. CD3 high,
scoreZ 2.5; (B) cases grouped into 4 risk groups based on CD3þ and CD68þ scores; CD3 high, scoreZ 2.5; and CD68 high, scoreZ 2.5; and (C) tumors
partitioned according to high vs. low CD68/CD3 ratio and CD68/CD3 high, score 41. (A) A total of 52 samples, whereas (B) and (C) includes 49 samples
owing to 3 samples that could not be evaluated for CD68. (Color version of ﬁgure is available online.)
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same pattern of differential response and ranking of sub-
types based on levels of TIL and TAM counts were seen in
MI cases, that are almost exclusively of grade 3. Thus, our
data indicate that the strength of the induced immunological
response is an intrinsic character of the UC molecular
subtypes. Apart from the molecular differences existing
between Uro, GU, and SCCL cases, the subtypes also show
radically different growth patterns [2], both of which may
inﬂuence the level of immunological responses induced by
the host. In addition, the antitumor activity of TILs and
TAMs may also be dependent on costimulatory signals
from the microenvironment, which were not investigated in
this study.
The immunological response in NMI cases is lower than
in MI tumors, particularly, evident for Ta cases. The
presence of TILs did not have a detectable effect on tumor
progression, a ﬁnding also noted by Sharma et al. [4]. High
levels of CD68þ TAMs have been shown to be associated
with recurrence of NMI tumors [15]. In this cohort, the
presence of TAMs were associated to tumor progression.
Owing to the limited number of progression events in this
study, the association between CD68þ TAMs and progres-
sion needs to be investigated further.
High CD3þ score was found to be a good prognostic
factor in MI cases. This strengthens the conclusion that high
levels of inﬁltrating T cells have a protective effect
[4,5,16,17]. In contrast to previous reports [4,5], no signiﬁcant
association with patient outcome was observed for CTLs
(CD8þ) or Tregs (FOXP3þ). Investigating a possible com-
bined effect of T-cell and macrophage inﬁltration, we
identiﬁed an interaction between CD3 and CD68 in a Cox
regression model. The subsequent Kaplan-Meier analysis
indicated that the levels of CD68þ TAMs modulated the
effect of CD3þ TILs and, in particular, that the ratio of
CD68þ relative to CD3þ cells was the dominating factor, not
the absolute CD68þ counts. In multivariate analysis, bothclinical stage and CD68/CD3 ratio were independent sig-
niﬁcant predictors of survival with the ratio having the
stronger effect. Intriguingly, also in preoperative peripheral
blood samples, a high neutrophil/lymphocyte ratio has been
reported to be an indicator of poor prognosis after cystec-
tomy [18]. The ﬁndings reported here are similar to ﬁndings
in breast cancer, where a TAM/TIL ratio predicts outcome
as well as chemotherapy response for tumors of the basal-
like or HER2þ subtypes [19]. In colon cancer, levels of TILs
are strongly related to prognosis and the location of
inﬁltrating cells is critical [20]. In the current study, separate
analysis of stromal and intratumoral compartments did not
improve outcome prediction, although it should be noted
that tumors intermixed with stroma in the TMA cores were
not analyzed. The effect of localization and the effect of
more detailed subsets of TILs and TAMs merit additional
studies. In summary, our results indicate that for MI UC
treated with radical cystectomy clinical stage combined with
a tumor CD68/CD3 ratio is a valuable tool for prognostica-
tion. The prognostic value of a CD68/CD3 ratio needs to be
independently validated, preferably using a larger cohort of
MI samples.5. Conclusions
The molecular subtypes of UC display immunological
responses at different levels. A high CD68/CD3 ratio
identiﬁes a bad prognosis group among MI UC cases.
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